Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000450910p
Ethics application status
Not yet submitted
Date submitted
20/03/2020
Date registered
6/04/2020
Date last updated
6/04/2020
Date data sharing statement initially provided
6/04/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Nanofat: a novel therapeutic approach for vocal cord scar
Scientific title
Effect of nanofat injection for vocal cord scar on voice-related quality of life and stroboscopic measures
Secondary ID [1] 300838 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Vocal cord insufficiency 316723 0
vocal cord scar
 316807 0
Condition category
Condition code
Surgery 314970 314970 0 0
Surgical techniques
Respiratory 315136 315136 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Nanofat involves mechanically emulsifying and filtering harvested fat. The technique does not require the use of a surgical laboratory, proteolytic enzyme reagents, or specialised equipment. Studies have shown nanofat to contain stromal vascular fraction (SVF) - a non-adipocyte, supportive component of harvested fat and contains a complex population of fibroblasts, macrophages, immune regulatory cells, and a high density of adipocyte-derived stem cells (ADSC).

This study will investigate the role of nanofat injection in vocal fold scar. Patients in this arm will either receive up to 1 mL of dexamethasone (4 mg/mL) versus up to 1 mL of nanofat as a superficial sub-epithelial vocal fold injection into the area of scar.

The senior researcher (PP, ENT surgeon) will perform all injections.
All injections would take place at a tertiary hospital setting in an operating theatre under general anaesthetic. Fat is processed on-site to isolate cells. The fat is harvested from the patient (patients' autologous fat). The sieving process will be the same as the technique already described in the literature by Tonnard et al. The harvested fat will be mechanically emulsified by shifting the sample between two 10-mL syringes connected to each other by Luer-Lok connection. The fat then becomes an emulsion after 30 passes. Following the emulsification process, the liquid is filtered for injection. The harvesting process should take no longer than 30 minutes. All injections occur under general anaesthetic and direct microlaryngoscopy. The entire procedure should be completed in one hour. The harvest and intervention administration occurs under the same general anaesthetic.

The dose administered is difficult to be quantified. This is because different patients will have different degrees of vocal cord scar in addition to patient anatomical variation. In addition, it is also difficult to quantify the exact amount of grafted nanofat, because some may extrude from the injection site after removing the needle. The amount injected at the time of the procedure will be recorded by the operator.
Intervention code [1] 317162 0
Treatment: Surgery
Intervention code [2] 317163 0
Treatment: Other
Comparator / control treatment
Researchers will compare nanofat injection for vocal cord scar to steroid injection (dexamethasone 4 mg/mL)
Control group
Active

Outcomes
Primary outcome [1] 323280 0
Patient reported voice-related quality of life measures
(VoiSS and perceived overall voice impairment on VAS)
Timepoint [1] 323280 0
3, 6, and 12 months (primary timepoint) post-injection
Secondary outcome [1] 381416 0
Vibratory properties measured on stroboscopy by a blinded, trained , independent rater
Timepoint [1] 381416 0
pre-procedure
post-procedure at 1 week, 3 months, 6 months, 12 months
Secondary outcome [2] 381417 0
Harmonic: noise ratio measured on Phontary Aerodynamic System Measurement tool
Timepoint [2] 381417 0
pre-procedure,
3, 6, and 12 months from intervention
Secondary outcome [3] 381418 0
phonation threshold pressure measured on Phontary Aerodynamic System Measurement tool
Timepoint [3] 381418 0
Pre-procedure
3, 6, and 12 months post-procedure
Secondary outcome [4] 381419 0
Subglottic pressure measured on Phontary Aerodynamic System Measurement tool
Timepoint [4] 381419 0
Pre-procedure
3, 6, and 12 months post-procedure
Secondary outcome [5] 381424 0
Perturbation measured on stroboscopy
Timepoint [5] 381424 0
Pre-procedure
3, 6, and 12 months post-procedure
Secondary outcome [6] 381425 0
fundamental frequency measured on stroboscopy
Timepoint [6] 381425 0
Pre-procedure
3, 6, and 12 months post-procedure
Secondary outcome [7] 381426 0
intensity measured on stroboscopy
Timepoint [7] 381426 0
Pre-procedure
3, 6, and 12 months post-procedure
Secondary outcome [8] 381427 0
s:z ratio measured on stroboscopy
Timepoint [8] 381427 0
Pre-procedure
3, 6, and 12 months post-procedure

Eligibility
Key inclusion criteria
vocal cord scar
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
evidence of other vocal fold abnormalities (granuloma, polyps, sulcus or other pathology affecting vocal fold vibration), previous history of glottic cancer, previous laser resection of the vocal fold, prior radiotherapy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/05/2020
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
20
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 305295 0
Hospital
Name [1] 305295 0
Monash Health
Country [1] 305295 0
Australia
Primary sponsor type
Hospital
Name
Department of Otolaryngology, Monash Health
Address
Department of ENT
823-65 Centre Road
Bentleigh East VIC 3165
Country
Australia
Secondary sponsor category [1] 305656 0
None
Name [1] 305656 0
Address [1] 305656 0
Country [1] 305656 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 305633 0
Monash Health Human Research Ethics Committee
Ethics committee address [1] 305633 0
Ethics committee country [1] 305633 0
Australia
Date submitted for ethics approval [1] 305633 0
30/04/2020
Approval date [1] 305633 0
Ethics approval number [1] 305633 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 101030 0
Dr Daniel Wong
Address 101030 0
Monash Health
Department of ENT
Rear 867 Centre Rd
Bentleigh East 3165 VIC
Country 101030 0
Australia
Phone 101030 0
+61 39928 8799
Fax 101030 0
Email 101030 0
danjywong@outlook.com
Contact person for public queries
Name 101031 0
Debra Phyland
Address 101031 0
Monash Health
Department of ENT
Rear 867 Centre Rd
Bentleigh East 3165 VIC
Country 101031 0
Australia
Phone 101031 0
+61 39928 8799
Fax 101031 0
Email 101031 0
debra.phyland@monashhealth.org
Contact person for scientific queries
Name 101032 0
Paul Paddle
Address 101032 0
Monash Health
Department of ENT
Rear 867 Centre Rd
Bentleigh East 3165 VIC
Country 101032 0
Australia
Phone 101032 0
+6139928 8799
Fax 101032 0
Email 101032 0
paul.paddle@monashhealth.org

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
7418Ethical approval    Ethical approval is being obtained through the Mon... [More Details]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.